Partnering Opportunities that Improve Clinical Outcomes

The success of our partnerships depends on mutual commitment to scientific and business goals. We welcome collaborations where there is a good strategic fit in areas where we can make a significant contribution. These areas include:

• Candidate selection
• First-in-human studies (Phase 1a and 1b)
• Proof of concept studies (Phase 2a)
• Efficacy studies (Phase 3)
• Post-launch studies (Phase 4)

Business Development Strategy

KineMed's partnering goals are (1) to enhance the successful development of our partners' compounds and (2) to work with pharmaceutical companies and leading academic institutions to broaden and deepen the KineMed TM and PM platform and to demonstrate its ability to robustly predict long-term clinical outcomes in its core therapeutic areas.

Since its founding, KineMed has formed more than 25 different clinical and/or preclinical development relationships with major pharmaceutical companies, top-tier biotechnology companies, the NIH, and medical research foundations. These collaborations have provided non-dilutive funding to enable KineMed to develop novel methods for the pre-clinical and clinical assessment of future potential medicines across a range of therapeutic areas and indications:

• Reverse cholesterol transport for atherosclerosis
• De novo lipogenesis and triglyceride synthesis in diabetes and obesity
• Insulin resistance in diabetes and metabolic syndrome
• B cell proliferative rates in Chronic Lymphocytic Leukemia
• A-Beta amyloid kinetics in Alzheimer's disease
• Modulation of microtubule kinetics and axonal transport in neurodegenerative diseases
• Stimulation of neurogenesis, neuronal stem cell proliferation, and synaptogenesis in diorders of mood and / or cognition
• Assessment of rates of collagen synthesis in scleroderma and, lung, liver and kidney fibrosis
• Muscle protein production in cachexia and sarcopenia